Injection types in nursing education: what the science says

What's this video probably claiming?

This TikTok from a creator associated with the Faculty of Health Sciences at UASD (Universidad Autónoma de Santo Domingo) is almost certainly a student nursing education post covering the different types of injections, likely including intramuscular (IM), subcutaneous (SC), intradermal (ID), and possibly intravenous (IV) routes. The hashtags #enfermeria and #FCS point squarely at a clinical training context. In the peptide space, this matters because many bioactive peptides, including BPC-157, TB-500, and CJC-1295, are administered via SC or IM injection. A student walking through injection technique is probably not making therapeutic claims, but the framing of injection education on a platform saturated with peptide promotion content still deserves scrutiny. Viewers may land here looking for dosing guidance, not anatomy review.

What does the science actually show?

The pharmacokinetics of injection route are well established. Subcutaneous absorption is slower and more sustained than IM, which matters for peptides with short half-lives. CJC-1295 without DAC, for example, has a half-life of roughly 30 minutes when administered SC, versus the DAC version extending to 6 to 8 days (Teichman et al., 2006, Journal of Clinical Endocrinology and Metabolism). Ipamorelin peaks at approximately 15 to 30 minutes post-SC injection with a half-life under 2 hours. Intradermal injection, often cited for GHK-Cu in cosmetic contexts, has extremely limited absorption depth, around 1 to 2mm, which constrains systemic bioavailability. None of these routes have been validated in large-scale human clinical trials for peptide therapy specifically. Most pharmacokinetic data comes from Phase I or Phase II trials with small sample sizes, often under 50 subjects.

Where does the social media noise diverge from clinical reality?

TikTok nursing content, especially student-generated posts, often gets repurposed by peptide communities as informal dosing tutorials. That is a real problem. A video explaining "how IM injections work" can quickly become a comment section full of people asking whether they should inject BPC-157 IM or SC for a knee injury. The answer, by the way, is not settled: Sikiric et al. (2018, Current Pharmaceutical Design) documented healing effects in rodent models via IP injection, which does not translate cleanly to SC or IM protocols in humans. No approved clinical standard exists. Injection site rotation, needle gauge selection (typically 25 to 29 gauge for SC peptide use in research settings), and sterility protocols are all areas where social media guidance frequently falls short of what actual clinical training requires. A 30-second TikTok cannot replace that training.

What should you actually know?

If you are watching nursing education content to understand how to self-administer peptides at home, stop and reframe your approach. Injection technique is a clinical skill taught over weeks in supervised settings, not a TikTok tutorial. Beyond technique, the regulatory status of most research peptides means there is no standardized sterility testing or dosing guidance available to consumers. Compounded peptides are not equivalent to pharmaceutical-grade agents used in clinical trials. The FDA placed BPC-157 and TB-500 on its category 2 list of bulk drug substances in 2023, restricting their use in compounded preparations. If you are genuinely interested in peptide therapy, the right path is a licensed telehealth provider who can assess your individual history, not injection anatomy content from a student nursing account.